Pancreatic Insufficiency Clinical Trial
Official title:
Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis
The purpose of this study is to provide the necessary data and experience to design a larger, full scale clinical trial to determine if a certain medicine (repaglinide), which increases the amount of insulin secreted by the pancreas, can improve the nutritional status and pulmonary function of adolescents and young adults with cystic fibrosis and prediabetes by improving blood glucose control. The investigators are also trying to determine the relationship between systemic inflammatory factors and glucose impairment.
As people with Cystic Fibrosis (CF) are living well into adulthood new complications are
arising. CF-Related Diabetes (CFRD) has emerged as a major complication. Years prior to the
diagnosis of CFRD, patients have decreasing insulin secretion, glucose intolerance,
deteriorating pulmonary function, and nutritional impairment. There are no current standard
recommendations for the treatment of CF patients with prediabetes, and there is little
evidence that treatment of this prediabetic state in CF patients will prevent the
deterioration of the lung function, nutritional status and potentially slow the progression
to manifest CFRD.
To determine the feasibility of testing this hypothesis, we will perform a pilot,
double-blinded, randomized controlled trial in 20 CF pancreatic insufficient patients ages
of 12 to 24 years old with impaired glucose tolerance test (IGT) or CFRD without fasting
hyperglycemia (CFRD-No FH) and assign them to either placebo or Repaglinide 0.5 mg PO 3 - 4
times a day before meals for two years. Patients will monitor their blood glucose daily and
will be followed every 3 months for 2 years to determine changes in nutritional status by
BMI and DEXA, lung function tests, frequency of hospitalizations, antibiotic courses, and
degree of glucose tolerance, insulin secretion and insulin sensitivity.
In addition, based on the evidence of increased inflammation in type 2 diabetes, correlation
of systemic inflammatory response at different degrees of glucose tolerance and after
treatment, will be assessed in these subjects, as well as in another 20 CF pancreatic
insufficient matched patients with normal glucose tolerance who will be studied once without
intervention
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03279653 -
Pancreatic Exocrine Insufficiency After Bariatric Surgery
|
N/A | |
Recruiting |
NCT01851694 -
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
|
N/A | |
Completed |
NCT01710644 -
Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
|
Phase 1/Phase 2 | |
Completed |
NCT01988350 -
Pancreatic Insufficiency Secondary to Tobacco Exposure
|
N/A | |
Active, not recruiting |
NCT01012908 -
Clinical Non-Inferiority of Pancreatic Enzymes (Norzyme ® - Bergamo) Compared To Creon ® (Solvay Pharmaceutical) in Patients With Exocrine Pancreatic Insufficiency
|
Phase 2/Phase 3 | |
Completed |
NCT01879228 -
Effect of Chronic Incretin-based Therapy in Cystic Fibrosis
|
N/A | |
Completed |
NCT00705978 -
Creon 40,000 for Treatment of PEI (Pancreatic Exocrine Insufficiency) Due to Chronic Pancreatitis
|
Phase 3 | |
Completed |
NCT00095732 -
Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency
|
Phase 2 | |
Completed |
NCT00513682 -
Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)
|
Phase 3 | |
Recruiting |
NCT05466838 -
PERT to Improve Quality of Life in Patients Undergoing Pancreaticoduodenectomy: A Pilot Randomized Controlled Trial
|
N/A | |
Completed |
NCT02979340 -
MRI to Characterize and Predict CF Liver Disease in PUSH Cohort
|
||
Completed |
NCT00432861 -
Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis
|
Phase 3 | |
Completed |
NCT00406536 -
Study of LYM-X-SORB™ to Improve Fatty Acid and Choline Status in Children With CF and PI
|
Phase 2 | |
Completed |
NCT01144507 -
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis
|
||
Completed |
NCT05700604 -
Hypoglycemia and Glucagon Response in CF
|
||
Terminated |
NCT02985801 -
PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03551691 -
Proton Pump Inhibitors (PPI) and Fat Absorption in Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI)
|
Phase 2 | |
Recruiting |
NCT03450772 -
Equivalence Study to Compare Two Strengths of Creon in China
|
Phase 3 | |
Completed |
NCT00572975 -
Malabsorption Blood Test:Toward a Novel Approach to Quantify Steatorrhea
|
Phase 4 | |
Completed |
NCT00880100 -
Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF)
|
Phase 3 |